292 related articles for article (PubMed ID: 24441399)
1. Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo.
Cesana D; Ranzani M; Volpin M; Bartholomae C; Duros C; Artus A; Merella S; Benedicenti F; Sergi Sergi L; Sanvito F; Brombin C; Nonis A; Serio CD; Doglioni C; von Kalle C; Schmidt M; Cohen-Haguenauer O; Naldini L; Montini E
Mol Ther; 2014 Apr; 22(4):774-85. PubMed ID: 24441399
[TBL] [Abstract][Full Text] [Related]
2. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy.
Montini E; Cesana D; Schmidt M; Sanvito F; Bartholomae CC; Ranzani M; Benedicenti F; Sergi LS; Ambrosi A; Ponzoni M; Doglioni C; Di Serio C; von Kalle C; Naldini L
J Clin Invest; 2009 Apr; 119(4):964-75. PubMed ID: 19307726
[TBL] [Abstract][Full Text] [Related]
3. Viral Vectors: The Road to Reducing Genotoxicity.
David RM; Doherty AT
Toxicol Sci; 2017 Feb; 155(2):315-325. PubMed ID: 27803388
[TBL] [Abstract][Full Text] [Related]
4. Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and gammac overexpression.
Ginn SL; Liao SH; Dane AP; Hu M; Hyman J; Finnie JW; Zheng M; Cavazzana-Calvo M; Alexander SI; Thrasher AJ; Alexander IE
Mol Ther; 2010 May; 18(5):965-76. PubMed ID: 20354504
[TBL] [Abstract][Full Text] [Related]
5. Insertional gene activation by lentiviral and gammaretroviral vectors.
Bokhoven M; Stephen SL; Knight S; Gevers EF; Robinson IC; Takeuchi Y; Collins MK
J Virol; 2009 Jan; 83(1):283-94. PubMed ID: 18945765
[TBL] [Abstract][Full Text] [Related]
6. Genotoxic potential of lineage-specific lentivirus vectors carrying the beta-globin locus control region.
Arumugam PI; Higashimoto T; Urbinati F; Modlich U; Nestheide S; Xia P; Fox C; Corsinotti A; Baum C; Malik P
Mol Ther; 2009 Nov; 17(11):1929-37. PubMed ID: 19707188
[TBL] [Abstract][Full Text] [Related]
7. Foamy Virus Vector Carries a Strong Insulator in Its Long Terminal Repeat Which Reduces Its Genotoxic Potential.
Goodman MA; Arumugam P; Pillis DM; Loberg A; Nasimuzzaman M; Lynn D; van der Loo JCM; Dexheimer PJ; Keddache M; Bauer TR; Hickstein DD; Russell DW; Malik P
J Virol; 2018 Jan; 92(1):. PubMed ID: 29046446
[TBL] [Abstract][Full Text] [Related]
8. Physiological promoters reduce the genotoxic risk of integrating gene vectors.
Zychlinski D; Schambach A; Modlich U; Maetzig T; Meyer J; Grassman E; Mishra A; Baum C
Mol Ther; 2008 Apr; 16(4):718-25. PubMed ID: 18334985
[TBL] [Abstract][Full Text] [Related]
9. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors.
Modlich U; Navarro S; Zychlinski D; Maetzig T; Knoess S; Brugman MH; Schambach A; Charrier S; Galy A; Thrasher AJ; Bueren J; Baum C
Mol Ther; 2009 Nov; 17(11):1919-28. PubMed ID: 19672245
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of lentiviral vectors harboring the proximal promoter of the vav proto-oncogene: a weak and efficient promoter for gene therapy.
Almarza E; Río P; Meza NW; Aldea M; Agirre X; Guenechea G; Segovia JC; Bueren JA
Mol Ther; 2007 Aug; 15(8):1487-94. PubMed ID: 17534266
[TBL] [Abstract][Full Text] [Related]
11. Monitoring for potential adverse effects of prenatal gene therapy: genotoxicity analysis in vitro and on small animal models ex vivo and in vivo.
Themis M
Methods Mol Biol; 2012; 891():341-70. PubMed ID: 22648780
[TBL] [Abstract][Full Text] [Related]
12. Aberrant Clonal Hematopoiesis following Lentiviral Vector Transduction of HSPCs in a Rhesus Macaque.
Espinoza DA; Fan X; Yang D; Cordes SF; Truitt LL; Calvo KR; Yabe IM; Demirci S; Hope KJ; Hong SG; Krouse A; Metzger M; Bonifacino A; Lu R; Uchida N; Tisdale JF; Wu X; DeRavin SS; Malech HL; Donahue RE; Wu C; Dunbar CE
Mol Ther; 2019 Jun; 27(6):1074-1086. PubMed ID: 31023523
[TBL] [Abstract][Full Text] [Related]
13. Biosafety challenges for use of lentiviral vectors in gene therapy.
Rothe M; Modlich U; Schambach A
Curr Gene Ther; 2013 Dec; 13(6):453-68. PubMed ID: 24195603
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional enhancers induce insertional gene deregulation independently from the vector type and design.
Maruggi G; Porcellini S; Facchini G; Perna SK; Cattoglio C; Sartori D; Ambrosi A; Schambach A; Baum C; Bonini C; Bovolenta C; Mavilio F; Recchia A
Mol Ther; 2009 May; 17(5):851-6. PubMed ID: 19293778
[TBL] [Abstract][Full Text] [Related]
15. Preventing and exploiting the oncogenic potential of integrating gene vectors.
Modlich U; Baum C
J Clin Invest; 2009 Apr; 119(4):755-8. PubMed ID: 19348042
[TBL] [Abstract][Full Text] [Related]
16. Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells.
Schambach A; Bohne J; Chandra S; Will E; Margison GP; Williams DA; Baum C
Mol Ther; 2006 Feb; 13(2):391-400. PubMed ID: 16226060
[TBL] [Abstract][Full Text] [Related]
17. Targeted expression of two proteins in neural retina using self-inactivating, insulated lentiviral vectors carrying two internal independent promoters.
Semple-Rowland SL; Eccles KS; Humberstone EJ
Mol Vis; 2007 Oct; 13():2001-11. PubMed ID: 17982424
[TBL] [Abstract][Full Text] [Related]
18. Optimized lentiviral vector design improves titer and transgene expression of vectors containing the chicken beta-globin locus HS4 insulator element.
Hanawa H; Yamamoto M; Zhao H; Shimada T; Persons DA
Mol Ther; 2009 Apr; 17(4):667-74. PubMed ID: 19223867
[TBL] [Abstract][Full Text] [Related]
19. Understanding lentiviral vector chromatin targeting: working to reduce insertional mutagenic potential for gene therapy.
Papayannakos C; Daniel R
Gene Ther; 2013 Jun; 20(6):581-8. PubMed ID: 23171920
[TBL] [Abstract][Full Text] [Related]
20. Effect of the internal promoter on insertional gene activation by lentiviral vectors with an intact HIV long terminal repeat.
Knight S; Bokhoven M; Collins M; Takeuchi Y
J Virol; 2010 May; 84(9):4856-9. PubMed ID: 20181689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
